

PATIENT IDENTIFICATION
Known allergies / medication sensitivities:

- | | |
|--|--|
| <input type="checkbox"/> NL Infusion Care, AR Gould, Presque Isle
Phone: 207-768-4589; Fax: 207-768-4183 | <input type="checkbox"/> NL Mary Dow Center, Ellsworth
Phone: 207-664-5584; Fax: 207-664-5485 |
| <input type="checkbox"/> NL Infusion Care, Blue Hill
Phone: 207-374-3995; Fax: 207-374-3970 | <input type="checkbox"/> NL Infusion Care, Mayo, Dover-Foxcroft
Phone: 207-564-4254; Fax: 207-564-4418 |
| <input type="checkbox"/> NL Infusion Care, CA Dean, Greenville
Phone: 207-695-5222; Fax: 207-695-4801 | <input type="checkbox"/> NL Mercy Cancer Care, Portland
Phone: 207-553-6868; Fax: 207-904-0917 |
| <input type="checkbox"/> NL Infusion Care, Brewer
Phone: 207-973-9785; Fax: 207-973-9788 | <input type="checkbox"/> NL Infusion Care, SVH, Pittsfield
Phone: 207-487-4052; Fax: 207-487-3995 |
| <input type="checkbox"/> NL Infusion Care, Waterville
Phone: 207-861-3380; Fax: 207-861-3348 | |

OP golimumab (Simponi Aria) (Paper)

Page 1 of 1

Diagnosis:

- Psoriatic arthritis
 Rheumatoid arthritis
 Ankylosing spondylitis
 Other _____

ICD10: _____

Hepatitis and Tuberculosis Serologies Completed: *Note: If NO, treatment will not be scheduled until results are available.

Hepatitis B: Yes No Date: ____/____/____ Result: _____
Hepatitis C: Yes No Date: ____/____/____ Result: _____
Quantiferon TB Gold Test OR T SPOT: Date: ____/____/____ Which test: _____ Result: _____

IV Access:

- Saline Lock:
 Insert peripheral Saline Lock; *may leave in for consecutive treatment days*
 Discontinue Saline Lock after therapy completed
- PICC Line:
 Routine PICC Line Care, labs and restoration
 Discontinue PICC Line (verify regimen is complete with provider prior to removing line)
- Porta cath / Central Access Device (Hickman, Triple lumen):
 Porta cath access, labs, restoration and de-access / Central Access Device use and care

Height: _____ cm Weight: _____ kg

Premedication:

- Acetaminophen (Tylenol) 650 mg, PO, ONCE
 Cetirizine (Zyrtec) 10 mg, PO, ONCE
 methylPREDNISolone 40 mg, Soln, IVP, ONCE
 methylPREDNISolone 125 mg, Soln, IVP, ONCE
 methylPREDNISolone _____ mg, Soln, IVP, ONCE

Medication:

golimumab (Simponi Aria) 2 mg/kg = _____ mg/100 mL 0.9% Sodium Chloride, IVPB, Infuse over 30 minutes

Treatment Schedule:

One time dose
Initial therapy: Weeks 0 and 4 then Every 8 weeks or Every _____ weeks 6 months
Maintenance: Every 8 weeks or Every _____ weeks Duration: 1 year

Other:



100000067

Date: _____ Time: _____
Provider Signature: _____ Print Name: _____
Phone: _____ Fax: _____
Pharmacy Signature: _____

PROVIDERS MUST EXERCISE INDEPENDENT CLINICAL JUDGMENT WHEN USING ORDER SETS
October 2024